A review of the design, synthesis and biological activity of the bicyclic hexapeptide tachykinin NK2 antagonist MEN 10627.
We review the reported data on the design, the conformational features and the pharmacological properties of the bicyclic peptide tachykinin NK2 receptor antagonist MEN 10,627 or cyclo(Met-Asp-Trp-Phe-Dap-Leu)cyclo(2 beta-5 beta). MEN 10,627 possesses a highly constrained structure characterized by two consecutive beta-turns, as confirmed by the almost coincident results of NMR and X-ray analyses. The compound has been efficiently synthesized by solid-phase methodology using either Boc or Fmoc strategies. It is quite stable to metabolic degradation and is endowed with high affinity and selectivity for NK2 receptor expressed in various species. At the hamster NK2 receptor MEN 10,627 is about 30-fold more potent than the nonpeptide NK2 receptor antagonist, SR 48,968, while the converse is true for the rabbit NK2 receptor. MEN 10,627 and SR 48,968 show comparable affinities for the human NK2 receptor. MEN 10,627 produces a long lasting inhibition of the response to the selective NK2 receptor agonist [beta Ala8]NKA(4-10) in the rat urinary bladder in vivo after intravenous, intranasal and intraduodenal administration. Therefore different administration routes are possible for this compound that overcomes the usual drawbacks for the application of peptides as drugs.
Quartara
L
L
Chemistry Research Department, A. Menarini Industrie Farmaceutiche Riunite, Firenze, Italy.
Pavone
V
V
Pedone
C
C
Lombardi
A
A
Renzetti
A R
AR
Maggi
C A
CA
D000818:Animals; D006224:Cricetinae; D015195:Drug Design; D006801:Humans; D008297:Male; D010456:Peptides, Cyclic / Q000138:chemical synthesis*; D011817:Rabbits; D051381:Rats; D018041:Receptors, Neurokinin-2 / Q000037:antagonists & inhibitors*
D010456:Peptides, Cyclic; D018041:Receptors, Neurokinin-2; C090951:MEN 10627